VX-787: Phase IIa started

Vertex disclosed in its 1Q12 earnings that it began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 2 doses of oral VX-787 for 5 days in about 140 healthy volunteers inoculated wi...